Lucie Obéric
A5009487344- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Eosinophilic Disorders and Syndromes
- Colorectal Cancer Treatments and Studies
- T-cell and Retrovirus Studies
- Breast Implant and Reconstruction
- RNA Research and Splicing
- Hepatitis C virus research
- Statistical Methods in Clinical Trials
- Vascular Tumors and Angiosarcomas
- Renal Diseases and Glomerulopathies
Institut universitaire du cancer de Toulouse Oncopole
2016-2025
Centre Hospitalier Universitaire de Toulouse
2014-2025
Institut Claudius Regaud
2020-2024
Center for Cancer Research
2024
Inserm
2024
Université de Toulouse
2024
Hôpital Purpan
2011-2021
Laboratoire de Physique des 2 Infinis Irène Joliot-Curie
2021
Sorbonne Université
2009-2020
Université Toulouse III - Paul Sabatier
2020
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose 375 mg per square meter body-surface area administered every 2 months for 3 years transplantation would prolong the duration response.
Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose our study was to identify factors may predict failure, particularly progression (EP), within the first month Characteristics 116 patients were analyzed at time decision (TD) use commercial CAR (axicabtagene ciloleucel, n = 49; tisagenlecleucel 67) and treatment (TT),...
Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice management of PCNSL.The French oculo-cerebral network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 centers. Data between 2011 and 2016 were retrospectively analyzed.We identified 1,002 immunocompetent (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment...
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy placebo elderly DLBCL who achieved a complete response (CR) or partial (PR) to R-CHOP induction. Methods Patients previously untreated other aggressive were 60 80 years...
Abstract Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem transplantation (ASCT); however, clinical practice, roughly half R/R LBCL are deemed unsuitable candidates ASCT. The axi-cel remains be ascertained transplant-ineligible patients. ALYCANTE, an open-label, phase 2 study, evaluated a 62 who were...
Abstract Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti‐PD‐1 not well known. We retrospectively investigated the salvage therapies for unsatisfactory therapy, assessed by PET‐CT according Lugano criteria, 30 R/R HL patients. Patients were...
Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell presenting with variable response rates probably to underlying molecular heterogeneity.To identify characterize PCNSL heterogeneity facilitate clinical translation, we carried out comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation features] in discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs validation formalin-fixed,...
Objective: Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival patients HIV-associated diffuse large B-cell (DLBCL), NHL subtype, has improved markedly recent years. We aimed to analyze characteristics and outcomes of DLBCL HIV-infected era modern combined antiretroviral therapy (cART). Design: PLWHIV were prospectively enrolled French ANRS-CO16 Lymphovir cohort between 2008 2015. compared treated R-CHOP) (rituximab,...
PURPOSE: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that young patients. An attenuated dose chemotherapy—cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)—is a good compromise between efficacy safety in very In combination R-CHOP (R2-CHOP), lenalidomide has an acceptable level toxicity may mitigate the negative non–germinal center B-cell–like phenotype. Lymphoma Study association conducted multicentric,...
Learning Objectives After completing this course, the reader will be able to: Outline clinical and biological features that would prompt a clinician to investigate an underlying malignancy in patient suffering from thrombotic microangiopathy.Conduct additional investigation diagnose or rule out malignancy.Formulate timely fashion adapted treatment plan for with cancer-associated microangiopathy. This article is available continuing medical education credit at CME.TheOncologist.com.
Abstract Non-Hodgkin B-cell lymphomas (B-NHLs) are a highly heterogeneous group of mature malignancies. Their classification thus requires skillful evaluation by expert hematopathologists, but the risk error remains higher in these tumors than many other areas pathology. To facilitate diagnosis, we have developed gene expression assay able to discriminate seven most frequent NHL categories. This relies on combination ligation-dependent RT-PCR and next-generation sequencing, addresses more...
Summary Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR‐2, addresses this knowledge gap reports on data collected from 240 relapsed/refractory MCL Europe were treated BTKi‐based therapy between July 2012 2018, had experienced disease progression while...
Findings among a cohort of 26 patients who had hematologic malignancies and hepatitis E virus (HEV) infection support that HEV can induce chronic hepatitis. However, 3-month course ribavirin rapid viral clearance, reducing the risk for enabling continuation cytotoxic treatments underlying malignancies.
JCO